Tango Therapeutics, Inc. (NASDAQ: TNGX) shares rocketed 36.28% higher Thursday, March 5, 2026, closing at $16.83 after the clinical-stage biotechnology company reported fourth-quarter and full-year 2025 financial results that exceeded expectations and highlighted advancing momentum in its precision oncology pipeline. The stock opened at $12.20, soared to an intraday high of $16.97 and traded as low as $11.80, with volume exploding to more than 17 million shares — far above average — as investors piled in on the positive update.

Tango Therapeutics
Tango Therapeutics

The rally marked Tango's strongest single-day gain in recent memory, pushing its market capitalization above $2.2 billion and lifting shares near the upper end of their 52-week range ($1.03 low to $16.97 high). Year-to-date performance has been volatile but positive amid biotech sector headwinds, with the March surge recouping prior losses and reflecting renewed confidence in the company's MTAP-deleted cancer focus.

Tango reported collaboration revenue of $62.4 million for full-year 2025, up sharply from $30.0 million in 2024, primarily from recognition of deferred revenue tied to its Gilead partnership. Research and development expenses declined to $132.2 million from $143.9 million, reflecting disciplined spending. The net loss narrowed to $101.6 million ($0.87 per share) from $130.3 million ($1.19 per share) the prior year. Cash, cash equivalents and marketable securities stood at $343.1 million as of December 31, 2025, providing runway into 2028 — a key positive for a clinical-stage biotech.

CEO Malte Peters, M.D., emphasized execution across the portfolio in prepared remarks. Lead candidate vopimetostat (TNG462), a PRMT5 inhibitor, continues to show best-in-class potential in MTAP-deleted tumors. The company remains on track to initiate a pivotal Phase 2/3 study of vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer in 2026. Enrollment progresses robustly in the ongoing Phase 1/2 combination trial with Revolution Medicines' RAS(ON) inhibitors in second-line-plus MTAP-deleted, RAS-mutated pancreatic and lung cancers, with initial data expected in 2026 that could inform an innovative path to a first-line pancreatic pivotal trial.

A new clinical supply agreement with Erasca for its pan-RAS molecular glue ERAS-0015 further explores vopimetostat in combination settings for pancreatic cancer and other indications. This builds on Tango's strategy to position PRMT5 inhibition as a preferred backbone for RAS-targeted therapies.

The earnings release and pipeline update fueled the surge, with analysts viewing the narrowed loss, extended runway and clear 2026 catalysts as supportive of upside. Consensus remains bullish, with recent initiations or reaffirmations including Wedbush's outperform rating and targets implying meaningful appreciation.

Challenges remain: Tango is pre-revenue beyond collaborations, faces typical biotech risks around trial outcomes and competition in precision oncology. No dividend is paid, and dilution risk exists if additional capital is needed. Yet the cash position mitigates near-term concerns.

Technical indicators show TNGX breaking out above key resistance near $13-$14, with momentum suggesting potential tests of $18-$20 if catalysts materialize. Volatility stays elevated, typical for small-cap biotech.

As trading resumes Friday, March 6, 2026 (pre-market indications held gains), focus shifts to upcoming investor conferences (Leerink Global Healthcare March 11) and data readouts. Tango's progress in MTAP-deleted cancers positions it as a high-conviction play in oncology, with Thursday's move underscoring investor enthusiasm for its execution and runway.